Baker Bros. Advisors Waives Right to Convert Shares Beyond 49.9% Voting Control

summarizeSummary

Kiniksa Pharmaceuticals and its largest institutional investor, Baker Bros. Advisors, agreed to limit Baker Bros.' voting power to below 49.9% through share conversions, providing clarity on corporate control.

check_boxKey Events · Ownership and Investor Activity · KNSA

• Deed of Waiver Executed

  Baker Bros. Advisors LP and Kiniksa Pharmaceuticals entered into a Deed of Waiver on May 21, 2026, which is also reported in a concurrent 8-K filing.

• Voting Control Limitation

  Baker Bros. irrevocably waived its right to convert Class A1 and Class B1 ordinary shares if such conversion would result in beneficial ownership exceeding 49.9% of the company's outstanding voting rights.

• Significant Potential Stake

  Without this limitation, Baker Bros. could potentially own approximately 42.5% of the Class A ordinary shares through conversion, highlighting the significance of the new cap.

• No Recent Transactions

  The reporting persons did not effect any transactions in Class A ordinary shares in the 60 days prior to the filing.

auto_awesomeAnalysis · KNSA · Life Sciences

Baker Bros. Advisors, a major institutional investor and 10% owner, has entered into a Deed of Waiver with Kiniksa Pharmaceuticals. This agreement prevents Baker Bros. from converting its Class A1 and Class B1 ordinary shares into voting shares if such conversion would result in them beneficially owning more than 49.9% of the company's outstanding voting rights. This clarifies the governance structure and limits the potential for a single shareholder to gain majority control through share conversions, providing stability and transparency for other shareholders.